RAF inhibitors, such as sorafenib, are clinically used in the treatment of papillary and anaplastic thyroid cancer cells with BRAF mutations, but their efficacy is limited and cannot completely prevent the recurrence of advanced tumours, such as melanoma and PTC.8, 9. Here, RAF1 is linked to melanoma.